MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 522998 | Name: BD1047 HBr
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BD1047 is a potent and selective Sigma-1 Receptor Antagonist. It has effects in animal studies suggestive of antipsychotic activity and may also be useful in the treatment of neuropathic pain. BD-1047 has >50-fold selectivity at σ1 over σ2 and also >100-fold selectivity over opiate, phencyclidine, muscarinic, dopamine, α1- & α2-adrenoceptor, 5-HT1, and 5-HT2.

Chemical Structure

BD1047 HBr
BD1047 HBr
CAS#138356-21-5 (HBr)

Theoretical Analysis

MedKoo Cat#: 522998

Name: BD1047 HBr

CAS#: 138356-21-5 (HBr)

Chemical Formula: C13H22Br2Cl2N2

Exact Mass: 0.0000

Molecular Weight: 437.04

Elemental Analysis: C, 35.73; H, 5.07; Br, 36.57; Cl, 16.22; N, 6.41

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,850.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
138356-20-4 (free base) 138356-21-5 (HBr)
Synonym
BD-1047; BD 1047; BD1047; BD-1047 HBr.
IUPAC/Chemical Name
N1-(3,4-dichlorophenethyl)-N1,N2,N2-trimethylethane-1,2-diamine dihydrobromide
InChi Key
WOALTFHGLDVJHK-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H20Cl2N2.2BrH/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11;;/h4-5,10H,6-9H2,1-3H3;2*1H
SMILES Code
CN(CCN(CCC1=CC=C(Cl)C(Cl)=C1)C)C.[H]Br.[H]Br
Appearance
Solid powder
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
BD1047 is a Sigma-1 Receptor Antagonist.
In vitro activity:
The administration of BD1047 significantly decreased the levels of mTOR and Camk2γ expression compared with those of the F group in the cultured N2a cells (P<0.01; Figs. 1 and 2). Moreover, BD1047 significantly increased the levels of GSK-3β expression compared with those of the F group in the cultured N2a cells (P<0.01; Fig. 3). Reference: Exp Ther Med. 2014 Feb;7(2):435-438. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881039/
In vivo activity:
To investigate the role of sigma-1 receptor in initiation of BCP (bone cancer pain), mechanical allodynia was measured in BCP rats after a continuous administration of the selective sigma-1 receptor antagonist BD1047 injection. A continuous drug administration of BD1047 (120 nmol/20 μL, once a day for 3 consecutive days) from day 5 to day 7 was used after inoculation with Walker 256 cells. There were no significant differences in baseline PWT (paw withdrawal threshold) among all groups (n = 10, P > 0.05). Compared with normal saline-treated (NS-treated) sham group, there were no remarkable changes of PWT in BD1047-treated sham group (P > 0.05; Figure 3). BCP group exhibited a decrease of PWT compared with sham group on day 5. Intrathecal administration of BD1047 significantly alleviated bone cancer induced mechanical allodynia compared with NS-treated BCP group (P < 0.01; Figure 3). Reference: Mediators Inflamm. 2015;2015:265056. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677253/
Solvent mg/mL mM
Solubility
Water 87.0 199.06
DMSO 50.0 114.41
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 437.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhu S, Wang C, Han Y, Song C, Hu X, Liu Y. Sigma-1 Receptor Antagonist BD1047 Reduces Mechanical Allodynia in a Rat Model of Bone Cancer Pain through the Inhibition of Spinal NR1 Phosphorylation and Microglia Activation. Mediators Inflamm. 2015;2015:265056. doi: 10.1155/2015/265056. Epub 2015 Nov 30. PMID: 26696751; PMCID: PMC4677253. 2. Kwon YB, Jeong YC, Kwon JK, Son JS, Kim KW. The Antinociceptive Effect of Sigma-1 Receptor Antagonist, BD1047, in a Capsaicin Induced Headache Model in Rats. Korean J Physiol Pharmacol. 2009 Dec;13(6):425-9. doi: 10.4196/kjpp.2009.13.6.425. Epub 2009 Dec 31. PubMed PMID: 20054487; PubMed Central PMCID: PMC2802301.
In vitro protocol:
1. Su DA, Jiang RY, Liu N, Ding LC, Wang DM, Yu HY, Yan ES, Zhu MH, Zhu B. Effects of BD1047, a σ1 receptor antagonist, on the expression of mTOR, Camk2γ and GSK-3β in fluvoxamine-treated N2a cells. Exp Ther Med. 2014 Feb;7(2):435-438. doi: 10.3892/etm.2013.1438. Epub 2013 Dec 5. PMID: 24396420; PMCID: PMC3881039.
In vivo protocol:
1. Zhu S, Wang C, Han Y, Song C, Hu X, Liu Y. Sigma-1 Receptor Antagonist BD1047 Reduces Mechanical Allodynia in a Rat Model of Bone Cancer Pain through the Inhibition of Spinal NR1 Phosphorylation and Microglia Activation. Mediators Inflamm. 2015;2015:265056. doi: 10.1155/2015/265056. Epub 2015 Nov 30. PMID: 26696751; PMCID: PMC4677253. 2. Kwon YB, Jeong YC, Kwon JK, Son JS, Kim KW. The Antinociceptive Effect of Sigma-1 Receptor Antagonist, BD1047, in a Capsaicin Induced Headache Model in Rats. Korean J Physiol Pharmacol. 2009 Dec;13(6):425-9. doi: 10.4196/kjpp.2009.13.6.425. Epub 2009 Dec 31. PubMed PMID: 20054487; PubMed Central PMCID: PMC2802301.
1: Zhu S, Wang C, Han Y, Song C, Hu X, Liu Y. Sigma-1 Receptor Antagonist BD1047 Reduces Mechanical Allodynia in a Rat Model of Bone Cancer Pain through the Inhibition of Spinal NR1 Phosphorylation and Microglia Activation. Mediators Inflamm. 2015;2015:265056. doi: 10.1155/2015/265056. Epub 2015 Nov 30. PubMed PMID: 26696751; PubMed Central PMCID: PMC4677253. 2: Jeong YC, Son JS, Kwon YB. The spinal antinociceptive mechanism determined by systemic administration of BD1047 in zymosan-induced hyperalgesia in rats. Brain Res Bull. 2015 Oct;119(Pt A):93-100. doi: 10.1016/j.brainresbull.2015.07.006. Epub 2015 Oct 1. PubMed PMID: 26434709. 3: Yoon SY, Kang SY, Kim HW, Kim HC, Roh DH. Clonidine Reduces Nociceptive Responses in Mouse Orofacial Formalin Model: Potentiation by Sigma-1 Receptor Antagonist BD1047 without Impaired Motor Coordination. Biol Pharm Bull. 2015;38(9):1320-7. doi: 10.1248/bpb.b15-00183. PubMed PMID: 26328487. 4: Su DA, Jiang RY, Liu N, Ding LC, Wang DM, Yu HY, Yan ES, Zhu MH, Zhu B. Effects of BD1047, a σ(1) receptor antagonist, on the expression of mTOR, Camk2γ and GSK-3β in fluvoxamine-treated N2a cells. Exp Ther Med. 2014 Feb;7(2):435-438. Epub 2013 Dec 5. PubMed PMID: 24396420; PubMed Central PMCID: PMC3881039. 5: Roh DH, Yoon SY. Sigma-1 receptor antagonist, BD1047 reduces nociceptive responses and phosphorylation of p38 MAPK in mice orofacial formalin model. Biol Pharm Bull. 2014;37(1):145-51. Epub 2013 Oct 24. PubMed PMID: 24152609. 6: Son JS, Kwon YB. Sigma-1 Receptor Antagonist BD1047 Reduces Allodynia and Spinal ERK Phosphorylation Following Chronic Compression of Dorsal Root Ganglion in Rats. Korean J Physiol Pharmacol. 2010 Dec;14(6):359-64. doi: 10.4196/kjpp.2010.14.6.359. Epub 2010 Dec 31. PubMed PMID: 21311675; PubMed Central PMCID: PMC3034114. 7: Fritz M, Klement S, El Rawas R, Saria A, Zernig G. Sigma1 receptor antagonist BD1047 enhances reversal of conditioned place preference from cocaine to social interaction. Pharmacology. 2011;87(1-2):45-8. doi: 10.1159/000322534. Epub 2010 Dec 29. PubMed PMID: 21196793. 8: Kwon YB, Jeong YC, Kwon JK, Son JS, Kim KW. The Antinociceptive Effect of Sigma-1 Receptor Antagonist, BD1047, in a Capsaicin Induced Headache Model in Rats. Korean J Physiol Pharmacol. 2009 Dec;13(6):425-9. doi: 10.4196/kjpp.2009.13.6.425. Epub 2009 Dec 31. PubMed PMID: 20054487; PubMed Central PMCID: PMC2802301. 9: Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Na HS, Lee JH. Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain. Anesthesiology. 2008 Nov;109(5):879-89. doi: 10.1097/ALN.0b013e3181895a83. PubMed PMID: 18946301. 10: McCracken KA, Bowen WD, de Costa BR, Matsumoto RR. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur J Pharmacol. 1999 Apr 16;370(3):225-32. PubMed PMID: 10334496. 11: Zambon AC, De Costa BR, Kanthasamy AG, Nguyen BQ, Matsumoto RR. Subchronic administration of N-[2-(3,4-dichlorophenyl) ethyl]-N-methyl-2-(dimethylamino) ethylamine (BD1047) alters sigma 1 receptor binding. Eur J Pharmacol. 1997 Apr 11;324(1):39-47. PubMed PMID: 9137911.